Screening period: 45 days~Double blind, double-dummy, primary analysis treatment period: 52 weeks~Open label extended treatment period: minimum of 52 weeks and maximum of 130 weeks~Follow up phone call: 30-37 days after end of treatment
This is a parallel arm, Phase 3, double-blind, double-dummy, active-comparator, 2 arm study to evaluate the efficacy and safety of daily oral venglustat versus intravenous Cerezyme infusions every two weeks for improvement or stabilization of the neurological manifestations and maintenance of systemic disease stability in participants aged ≥12 and <18 years and adult patients with Gaucher disease Type 3 (GD3) who have been treated with Enzyme Replacement Therapy (ERT) for at least 3 years.